Fig. 1: Selection of anti-PfAMA1 i-bodies. | Nature Communications

Fig. 1: Selection of anti-PfAMA1 i-bodies.

From: A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites

Fig. 1

a Outline of the strategy used for haplotype-distance biopanning the phage-displayed i-body library on 3D7 and W2mef recAMA1. The figure was created with BioRender.com and released under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. b ELISA of phage pools from the biopanning campaign against immobilised 3D7 recAMA1. c ELISA of phage pools from the biopanning campaign against immobilised W2mef recAMA1. In both campaigns, three independent experiments were performed as triplicates. Data are presented as mean values ± SD. d ELISA screening of individual i-bodies for Pf3D7AMA1 binding. Forty-eight clones were randomly selected from each biopanning campaign. i-bodies were expressed in E. coli and assessed for AMA1 binding in an ELISA. The binding of the i-bodies to the different AMA1 isoforms is represented as a heat map. Two independent experiments were performed as triplicates. e Sequence alignment of AMA1-specific i-bodies with the CDR1 and CDR3 sequences highlighted in blue. f Binding profile of i-bodies against Pf3D7, W2mef, 7G8, FVO, HB3, D10 recAMA1 isoforms and reduced and alkylated 3D7 AMA1 represented as a heat map where the darker the shade, the greater the binding. Three independent experiments were performed for each i-body. g Analysis of WD33 and WD34 binding to Pv and PcAMA1. Three independent experiments were performed. Data are presented as mean values ± SD. Source data are provided as a Source Data file.

Back to article page